In a breakthrough discovery, Dr. Kevin Eggan, Chief Scientific Officer of The
New York Stem Cell Foundation and Principal Faculty Member of the Harvard Stem
Cell Institute, has produced human stem cell lines from the cells of patients
afflicted with a version of amyotrophic lateral sclerosis (ALS), commonly known
as Lou Gehrig's disease. Eggan's work marks the first time scientists have
replicated in a laboratory the specific human cells affected by disease. His
experiments were funded by The New York Stem Cell Foundation and carried out by
a team of scientists working at Harvard and Columbia Universities.
"No
one has ever managed to isolate these neurons from a patient and grow them in a
dish," Eggan said. "Now we can make limitless supplies of the cells that die in
this awful disease." A further significance of his successful effort to derive
these new stem cells, Eggan said, is that it will open up new avenues for
scientists to study the root cause of ALS and many other diseases like it.
The work, published in the on-line edition of the journal
Science, is a major step toward scientists' belief that stem cell
research will eventually make it possible to treat patients suffering from
chronic diseases with stem cell-based treatments created from their own cells.
"Kevin Eggan is an international leader in stem cell research, and this
is a pathbreaking discovery, one that will bring us closer to the answers we
seek about the most devastating diseases of our time," said Susan L. Solomon,
co-founder and Chief Executive Officer of The New York Stem Cell Foundation. "We
are truly excited to have played a role in making it possible."
Eggan,
working with his colleagues John Dimos and Kit Rodolfa of the Harvard Stem Cell
Institute and two NYSCF post-doctoral research fellows, Paolo Di Giorgio and
Justin Ichida, derived induced pluripotent cells, known as iPS cells, from skin
cells of two elderly patients. A team led by Christopher Henderson with Hynek
Wichterle of Columbia University Motor Neurology Center coordinated patient
participation and collection of the skin cells.
IPS cells, which are a
form of stem cell, can be coaxed into cells that resemble the cells found in the
human body. In the case of the patients with ALS, Eggan's team induced them to
become motor neuron cells similar to the cells affected by the disease. The
process of creating iPS cells involves the use of genes, one of which is a
cancer-promoting gene, and as a result iPS cells are used as a way to study
disease, not as a therapy that can be transplanted into patients.
Dr.
Eggan will continue working with human embryonic stem cells, including SCNT
(somatic cell nuclear transfer), which has been the main focus of his work.
"It's essential to note that we couldn't possibly be where we are now without
first doing extensive work with human embryonic stem cells," he said. "It will
be essential to continue to do work with embryonic stem cells as they remain the
stem cell gold standard."
Scientists believe that because cells such as
the ones Eggan's team derived can be genetically matched to the cells from a
person suffering from the disease, they will provide a significant tool for
understanding how ALS and other diseases work, and how to prevent them -
permitting the disease, in effect, to be studied in a laboratory dish.
Scientists expect that eventually it will be possible to create similar cells
for the study of any number of diseases, from Parkinson's disease to diabetes
and cancer.
NYSCF funded the Eggan's team's portion of the research. The
foundation has supported Dr. Eggan's work since 2005.
"The New York Stem
Cell Foundation's support was integral to our ability to pursue this research,"
said Dr. Eggan. "Private funding continues to play a critical role in driving
the research that is helping us to understand diseases as never before. NYSCF is
a nimble and focused organization that can keep pace with the needs of
researchers as the pace of our work continues to intensify."
----------------------------
Article adapted by Medical News Today
from original press release.----------------------------
About The New York Stem Cell Foundation Founded in 2005,
The New York Stem Cell Foundation is a privately funded foundation dedicated to
furthering human stem cell research to advance the search for cures of the major
diseases of our time. The foundation opened the first privately funded human
embryonic stem cell laboratory in New York City in March 2006 to serve as a
"safe haven" where scientists can conduct advanced human embryonic stem cell
research free of federal restrictions. The organization supports scientists
engaged in stem cell research through grants, fellowships and symposia; runs
collaborative, state-of-the-art research facilities supported entirely with
private funds and directly focused on curing disease; and educates the public
about the importance and potential benefits of stem cell research.
Source: Adam Pockriss
New York Stem Cell Foundation
